ABSTRACT
Abstract Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modalities available to date for the management are systemic steroids, thalidomide, methotrexate, cyclophosphamide, azathioprine, minocycline, and apremilast but none of them is promising and safe. Mycobacterium indicus pranii is an atypical mycobacterium possessing strong immunomodulatory properties. The vaccine for this mycobacterium has been shown to have both immunotherapeutic and immunoprophylactic effects in multibacillary leprosy patients. We report a case of chronic recalcitrant erythema nodosum Leprosum which responded to Mycobacterium indicus pranii vaccine without any adverse effects, thereby suggesting its role as a novel therapeutic option in this reaction.
Subject(s)
Humans , Vaccines , Leprosy, Lepromatous/drug therapy , Erythema Nodosum/drug therapy , Leprosy, Multibacillary , MycobacteriumABSTRACT
Abstract Histoid leprosy is considered a rare form of lepromatous leprosy. Its peculiar clinical picture makes its diagnosis a challenging one, which can delay starting treatment and perpetuate the disease as endemic. In addition to representing a reservoir of bacilli, and being an important means of contamination, these patients have greater resistance to standard treatment. This is a report of a typical case of this rare presentation, aiming to share the knowledge and favor earlier diagnosis of the disease.
Subject(s)
Humans , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Leprosy , Mycobacterium lepraeABSTRACT
Resumen La lepra o enfermedad de Hansen es una de las clásicas enfermedades olvidadas que aún persiste en Perú. La infección es ocasionada por Mycobacterium leprae. La enfermedad varía en un amplio rango de manifestaciones desde la lepra tuberculoide (paucibacilar) hasta la lepromatosa (multibacilar). Se presenta el caso de un varón de 55 años, agricultor y extractor de madera, procedente de la Amazonia peruana, con lesiones cutáneas antiguas infiltrantes en la cara, cuello, tórax, abdomen y extremidades. La baciloscopia y estudio histológico de una biopsia de piel confirmaron la presencia de bacilos ácido-alcohol resistentes. Se concluyó, en forma tardía, que fue un caso de lepra lepromatosa nodular. Recibió terapia con rifampicina, dapsona y clofamizina por dos años con una lenta mejoría; no obstante, cursó con un eritema nodoso leproso (reacción tipo 2) con buena respuesta a corticoesteroides y talidomida.
Abstract Leprosy or Hansen's disease is one of the classic neglected diseases that still persists in Peru. The infection is caused by Mycobacterium leprae. The disease varies in a wide range of manifestations from tuberculoid (paucibacillary) to lepromatous (multibacillary) leprosy. We present the case of a 55-year-old man, farmer and wood extractor, from the Peruvian Amazon with old infiltrating cutaneous lesions on the face, neck, thorax, abdomen and extremities. The smear and biopsy examinations confirm the presence of acid-alcohol-resistant bacilli compatible with leprosy. It is concluded, with a long delay, it was a case of nodular lepromatous leprosy. He received therapy with rifampicin, dapsone and clofamizine for two years with slow progressive improvement; however, he presented an erythema nodosum leprosum (type 2 reaction) with response to corticosteroids and thalidomide.
Subject(s)
Humans , Male , Middle Aged , Leprosy, Lepromatous/diagnosis , Erythema Nodosum/diagnosis , Erythema Nodosum/pathology , Peru , Leprosy, Lepromatous/drug therapy , Erythema Nodosum/drug therapy , Delayed Diagnosis , LeprosyABSTRACT
Abstract Leprosy is an infectious disease with chronic evolution, caused by Mycobacterium leprae, an acid-fast bacillus that mainly affects the skin and peripheral nervous tissue. Many of the clinical manifestations of leprosy can mimic connective tissue diseases. The authors present the case of a 49-year-old woman who had been treated for four years for systemic lupus erythematosus in a rheumatological service. Skin biopsy of a plaque on the inguinal region was compatible with borderline lepromatous leprosy associated with a type 1 lepra reaction. The patient is undergoing treatment with multibacillary multidrug therapy, showing clinical improvement.
Subject(s)
Humans , Female , Leprosy, Borderline/drug therapy , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Leprosy/drug therapy , Drug Therapy, Combination , Leprostatic Agents/therapeutic use , Middle Aged , Mycobacterium lepraeABSTRACT
Resumen Los pacientes con lepra lepromatosa que han recibido tratamiento durante años, usualmente requieren seguimiento con biopsias de piel para detectar lesiones persistentes o si la baciloscopia es positiva, incluso si los valores son menores que los iniciales. Se presenta el caso de una mujer de 48 años de edad con lepra lepromatosa de 15 años de evolución, índice bacilar de 4 en el extendido directo y en la biopsia, que recibió tratamiento con múltiples medicamentos durante 32 meses, aunque lo recomendado por la Organización Mundial de la Salud (OMS) es una duración de 12 meses. Se tomó una biopsia de piel para determinar si la enfermedad estaba activa. Se observó inflamación dérmica difusa con numerosas células gigantes de tipo cuerpo extraño y macrófagos vacuolados (células de Virchow). Estas células, CD68 positivas, contenían material granular ácido-alcohol resistente positivo con inmunohistoquímica para BCG. Se encontraron bacilos fragmentados y el índice bacilar fue de 2. Se interpretó como una forma residual de lepra lepromatosa y se concluyó que la paciente no requería prolongar el tratamiento con múltiples medicamentos. Este perfil histológico se ha observado en casos similares, pero sin datos clínicos estas biopsias representan un reto diagnóstico. La acumulación de lípidos en estas células gigantes se debe a la destrucción bacilar y a la fusión de macrófagos vacuolados. Se revisó el papel de los lípidos del bacilo y del huésped en la patogenia de la lepra lepromatosa. En estos casos, no es necesario extender los 12 meses de tratamiento con múltiples medicamentos recomendados por la OMS. En el seguimiento de los pacientes, se recomienda contar con los hallazgos clínicos, la baciloscopia, la biopsia anual de piel y los títulos IgM antiglucolípido fenólico.
Abstract Patients with lepromatous leprosy that have received treatment for many years usually get follow up biopsies for persistent skin lesions or positive bacilloscopy even if the values are lower than in the initial bacilloscopy. We report the case of a 48-year old woman with long-standing lepromatous leprosy of 15 years of evolution, with a bacterial index of 4 in the direct smear and the initial skin biopsy. The patient was treated with multidrug therapy for 32 months although the treatment recommended by the World Health Organization (WHO) is only for 12 months. A skin biopsy was taken to determine if there was an active disease. We observed a diffuse dermal inflammation with numerous foreign body giant cells and vacuolated macrophages (Virchow´s cells). These cells contained granular acid-fast material that was also positive with immunohistochemistry for BCG. There were fragmented bacilli and the BI was 2. These cells were also strongly positive for CD68. The biopsy was interpreted as a residual form of lepromatous leprosy that did not require further multidrug therapy. We have observed similar histological profiles in several cases. The lack of clinical data makes it a histological challenge. The accumulation of lipids in these giant cells is due to bacillary destruction and fusion of vacuolated macrophages. We discuss here the role of bacillary and host lipids in the pathogenesis of lepromatous leprosy. We concluded that there was no need to extend the 12-month multidrug therapy recommended by WHO. Clinical findings, bacilloscopy, annual skin biopsy, and anti-phenolic glycolipid-I IgM titers are recommended procedures for the follow-up of these patients.
Subject(s)
Female , Humans , Middle Aged , Skin/pathology , Leprosy, Lepromatous/pathology , Giant Cells, Foreign-Body/pathology , Foam Cells/pathology , Skin/microbiology , Vacuoles , Biopsy , Antigens, Differentiation, Myelomonocytic/analysis , Leprosy, Lepromatous/drug therapy , Antigens, CD/analysis , Giant Cells, Foreign-Body/microbiology , Giant Cells, Foreign-Body/chemistry , Cell Wall/chemistry , Drug Therapy, Combination , Host-Pathogen Interactions , Foam Cells/microbiology , Foam Cells/chemistry , Leprostatic Agents/therapeutic use , Lipids/analysis , Mycobacterium leprae/isolation & purification , Mycobacterium leprae/chemistryABSTRACT
Abstract: Background: Erythema nodosum leprosum may appear before, during or after treatment of leprosy and is one of the main factors for nerve damage in patients. When it occurs or continues to occur after treatment, it may indicate disease recurrence and a new treatment may be instituted again. Objective: To evaluate the retreatment of patients with multibacillary leprosy who underwent standard treatment with multidrug therapy, but developed or continued to present reactions of erythema nodosum leprosum and/or neuritis 3-5 years after its end. Method: For this objective, a new treatment was performed in 29 patients with multibacillary leprosy who maintained episodes of erythema nodosum and/or neuritis 3-5 years after conventional treatment. Results: In general, we observed that 27 (93.10%) had no more new episodes after a follow up period of eight months to five years. In five of these patients the reason for the retreatment was the occurrence of difficult-to-control neuritis, and that has ceased to occur in all of them. Study limitations: Small number of patients.. Conclusion: In the cases observed, retreatment was an effective measure to prevent the occurrence of erythema nodosum leprosum and/or persistent neuritis.
Subject(s)
Humans , Male , Female , Leprosy, Lepromatous/drug therapy , Erythema Nodosum/drug therapy , Leprosy, Multibacillary/drug therapy , Neuritis/drug therapy , Recurrence , Time Factors , Leprosy, Lepromatous/microbiology , Treatment Outcome , Retreatment , Erythema Nodosum/microbiology , Leprosy, Multibacillary/microbiology , Leprostatic Agents/therapeutic use , Neuritis/microbiologyABSTRACT
RESUMEN Se describe un reporte de caso de un paciente del Sanatorio Agua de Dios Cundinamarca con diagnóstico de lepra lepromatosa histioide con sospecha de resistencia a la poliquimioterapia (PQT), evidenciando la importancia de los criterios clínicos para inicio de terapia alterna ante las limitaciones en los medios paraclínicos. La resistencia debe sospecharse y diagnosticarse tempranamente para evitar la progresión de la enfermedad; los criterios clínicos y paraclínicos ayudan a su confirmación diagnóstica, en los estudios bacteriológicos la escala semicuantitativa Colombiana debe reemplazarse por escala logarítmica de Ridley y Jopling, los estudios histopatológicos se practican en todo paciente con enfermedad de Hansen, los estudios de resistencia se están implementando en el país pero su acceso limita oportunidad para apoyo en el inicio terapéutico.(AU)
ABSTRACT This paper describes a case report of a patient from the Sanatorio Agua de Dios-Cundinamarca diagnosed with histioid lepromatous leprosy with suspected resistance to polychemotherapy (PQT), making evident the importance of clinical criteria for initiating an alternative therapy given the limitations of paraclinical examinations. Resistance should be suspected and diagnosed early to prevent the progression of the disease; clinical and paraclinical criteria help to confirm diagnosis. In bacteriological studies, the Colombian semiquantitative scale should be replaced by the Ridley-Jopling logarithmic scale. Histopathological studies are conducted on all patients with Hansen's disease. Research on resistance is being implemented in the country, but its access limits the opportunity for support in therapy initiation.(AU)
Subject(s)
Humans , Drug Resistance , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/epidemiology , Rifampin/therapeutic use , Colombia/epidemiology , Dapsone/administration & dosageABSTRACT
Abstract: One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
Subject(s)
Humans , Male , Adult , Leprosy, Lepromatous/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Erythema Nodosum/drug therapy , Etanercept/therapeutic use , Thalidomide/therapeutic use , Prednisone/therapeutic use , Immunosuppressive Agents/therapeutic useABSTRACT
Abstract Brazil has the second largest number of leprosy cases in the world; nevertheless, late diagnosis is common. We report the case of a male patient with pain and numbness in both hands and feet for six years with positive rheumatoid factor and anticardiolipin under rheumatoid arthritis treatment for five years. Examination revealed diffuse cutaneous infiltration and leonine facies, characteristic features of lepromatous leprosy. Autoantibodies such as rheumatoid factor and anticardiolipin are markers of rheumatic autoimmune diseases, but their presence is also described in leprosy. We report the present case in order to alert health professionals to remember leprosy, even in areas where the disease is considered eliminated as a public health problem, avoiding misinterpretations of serologic findings and misdiagnosis.
Subject(s)
Humans , Male , Middle Aged , Arthritis, Rheumatoid/diagnosis , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/pathology , Leprosy, Lepromatous/drug therapy , Diagnosis, Differential , Neglected Diseases/diagnosis , Neglected Diseases/pathology , Neglected Diseases/drug therapyABSTRACT
La lepra es una infección crónica, granulomatosa, producida por Mycobacterium leprae, que afecta piel y nervios periféricos. Se describen dos tipos de reacciones leprosas: tipo I y tipo II, las que corresponden a cuadros agudos que exacerban la enfermedad. Estas leproreacciones pueden ocurrir antes, durante o después del tratamiento. Se presenta el caso de un paciente masculino que acude a consultar con lesiones cutáneas y resultado de biopsia de piel con diagnóstico de lepra. Se inicia tratamiento multidroga OMS-MB1. Posteriormente presenta una leproreacción tipo I, por lo que se le realiza tratamiento con prednisona.
Leprosy is a chronic granulomatous infection of the skin and peripheral nervous system produced by Mycobacterium leprae. Two types of acute leprosy reactions have been described: type I and type II. These reactions can occur before, during or after treatment. We present the case of an adult male patient presenting with skin lesions and skin biopsy diagnostic for leprosy. A multidrug WHO-MB 1 treatment was initiated, after which he presents with type I lepra reaction requiring corticosteroids.
Subject(s)
Humans , Male , Middle Aged , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Clofazimine/adverse effects , Drug Therapy, Combination/adverse effects , Erythema Nodosum/chemically induced , Rifampin/adverse effects , Biopsy , Dapsone/adverse effects , Leprosy, Multibacillary/pathology , Leprostatic Agents/adverse effectsSubject(s)
Humans , Female , Adult , Sarcoma, Kaposi/chemically induced , Sarcoma, Kaposi/pathology , Skin Neoplasms/chemically induced , Skin Neoplasms/pathology , Adrenal Cortex Hormones/adverse effects , Immunohistochemistry , Leprosy, Lepromatous/drug therapy , Herpesvirus 8, Human/isolation & purification , Iatrogenic DiseaseABSTRACT
Abstract Lucio’s phenomenon is an uncommon reaction characterized by severe necrotizing cutaneous lesions that occurs in patients with Lucio’s leprosy and lepromatous leprosy. It is considered by some authors as a variant of type 2 or 3 reaction. Death can occur because of blood dyscrasia or sepsis. Precipitating factors include infections, drugs and pregnancy. We report a 31-year-old female patient exhibiting both clinical and histopathological features of lepromatous leprosy and Lucio’s phenomenon presenting favorable response to treatment. We complement our report with a literature review of the Brazilian cases of Lucio’s phenomenon published in Portuguese and English.
Subject(s)
Humans , Female , Adult , Skin Ulcer/pathology , Leprosy, Lepromatous/pathology , Skin/pathology , Skin Ulcer/drug therapy , Biopsy , Severity of Illness Index , Brazil , Leprosy, Lepromatous/drug therapy , Treatment Outcome , NecrosisABSTRACT
BACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL. .
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Erythema Nodosum/drug therapy , Leprostatic Agents/administration & dosage , Leprosy, Borderline/drug therapy , Leprosy, Lepromatous/drug therapy , Thalidomide/administration & dosage , Dose-Response Relationship, Drug , Erythema Nodosum/prevention & control , Follow-Up Studies , Leprosy, Borderline/prevention & control , Leprosy, Lepromatous/prevention & control , Severity of Illness Index , Sex Factors , Treatment OutcomeABSTRACT
Lucio's phenomenon represents a serious cutaneous necrotizing reaction, which can occur with Lucio's leprosy and also in other forms of lepromatous leprosy. The authors discuss the case of a 63-year-old male patient presenting with ulcers and necrotic cutaneous lesions on the limbs, torso and face, associated with recurring sinusitis, hoarseness and a weight loss of 25 kilos over the last year. Bacilloscopy of intradermal scrapings showed a bacilloscopic index of 5 and the histopathological findings were compatible with the diagnosis of Lucio's phenomenon. The chosen treatment was exclusively multibacillary multidrug therapy, resulting in important dermatological improvement after one month of therapy. The authors present an impressive case of Lucio's phenomenon with an exceptional response to treatment exclusively with multibacillary multidrug therapy.
O fenômeno de Lúcio representa uma reação cutânea necrosante grave que pode ocorrer na hanseníase de Lúcio e em outras formas de hanseníase virchowiana. Os autores relatam o caso de um paciente masculino de 63 anos de idade apresentando há um ano lesões ulceronecróticas nos membros, lóbulos auriculares e tronco, associadas a sinusite de repetição, rouquidão e perda ponderal de 25 kg. A baciloscopia de raspado intradérmico mostrou índice baciloscópico de 5 e o exame histopatologico foi compatível com fenômeno de Lúcio. O tratamento instituído foi exclusivamente com poliquimioterapia multibacilar (PQT-MB), havendo melhora importante do quadro cutâneo após um mês de tratamento. Os autores apresentam um caso exuberante de fenômeno de Lúcio que obteve excelente resposta ao tratamento somente com PQT-MB.
Subject(s)
Humans , Male , Middle Aged , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/drug therapy , Biopsy , Drug Therapy, Combination/methods , Leprosy, Lepromatous/pathology , Necrosis , Time Factors , Treatment OutcomeABSTRACT
Introducción. Colombia es el país de América con mayor proporción de casos nuevos de lepra con discapacidad grave. Para disminuir tal discapacidad se requiere el control de las reacciones, principal causa del daño neural en esta enfermedad. Objetivo. Describir las características clínicas y epidemiológicas y el tratamiento de los pacientes con reacciones de tipo 1 y 2 que consultaron al Centro Dermatológico Federico Lleras Acosta. Materiales y métodos. Se trata de un estudio descriptivo que incluyó la población de pacientes con diagnóstico clínico de reacciones de tipo 1 y de tipo 2 por lepra, que acudieron al centro entre los años 2003 y 2009. Resultados. Se estudiaron 96 reacciones, 35 del tipo 1 y 61 del tipo 2. El 75 % de los pacientes provenía de los departamentos de Tolima, Cundinamarca, Santander y Boyacá. El 56 % de las reacciones de tipo 1 se presentaron antes de iniciar la poliquimioterapia para la lepra; el dermatólogo tratante consideró que las reacciones que se presentaron después de suspender la poliquimioterapia eran recaídas. El 94 % de las reacciones de tipo 1 se trataron con corticoides orales. El 97 % de los pacientes con reacciones de tipo 2 presentaron eritema nudoso, y todos se trataron con talidomida. Conclusiones.La clínica de la reacción de tipo 1 puede orientar al diagnóstico de la lepra en un paciente sin el antecedente de esta enfermedad (56 %). La reacción de tipo 1 que se inicia después de suspender la poliquimioterapia para la lepra, podría ser una manifestación de recaída de la enfermedad. La reacción de tipo 2 es más frecuente en hombres, con una relación hombre a mujer de 4:1. El 97 % de los pacientes con reacción de tipo 2 presentó eritema nudoso.
Introduction: Colombia is the country in America with the highest proportion of new cases leprosy with severe disability. To decrease such disability it is necessary to control these reactions, the main cause of nerve damage in leprosy. Objective: To describe the clinical and epidemiological characteristics and the treatment of patients with type 1 and 2 leprosy reactions who consulted the Centro Dermatológico Federico Lleras Acosta. Materials and methods: It is a descriptive study which included patients with clinical diagnoses of type 1 and 2 reactions who were seen in the center between 2003 and 2009. The town of origin of the patients, their age, clinical features and treatments were analysed. Results: We studied 96 reactions in 87 patients, 35 type 1 and 61 type 2 reactions; 75% of the patients came from the departments of Tolima, Cundinamarca, Santander and Boyacá; 77% of type 1 reaction occurred before the beginning of multidrug therapy for leprosy. The reactions that started after stopping the multidrug therapy were considered as a leprosy relapse. Conclusions: Correct identification of type 1 reaction by the general practitioner will allow the diagnosis of leprosy in a large percentage of patients. The type 1 reaction that begins after stopping the leprosy multidrug therapy may be a manifestation of a relapse of the disease.
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Erythema Nodosum/epidemiology , Leprosy/pathology , Colombia/epidemiology , Cytokines , Drug Therapy, Combination , Erythema Nodosum/etiology , Immune Complex Diseases/epidemiology , Immune Complex Diseases/etiology , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/complications , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/epidemiology , Leprosy, Lepromatous/immunology , Leprosy, Paucibacillary/drug therapy , Leprosy, Paucibacillary/pathology , Leprosy, Paucibacillary/physiopathology , Leprosy/drug therapy , Leprosy/epidemiology , Leprosy/physiopathology , Recurrence , Tertiary Care Centers/statistics & numerical dataABSTRACT
Afine del 2001, nuestro país, con acción mancomunada del Ministerio de Salud Pública y Bienestar Social, la Asociación Alemana de Ayuda al enfermo de Lepra (DAHW), la Oficina Sanitaria Panamericana ( OPS ) y el Comité de iglesias Mennonitas del Paraguay, ha conseguido reducir la tasa de prevalencia país a menos de 1 caso por 10.000 habitantes.
Subject(s)
Humans , Child , Adult , Leprostatic Agents , Primary Health Care/standards , Leprosy, Lepromatous/drug therapy , Disease Management , Patients , Clofazimine/therapeutic use , Dapsone/therapeutic use , Patient Care Team/organization & administration , Drug Therapy, Combination/methods , Rifampin/therapeutic useABSTRACT
This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.
Subject(s)
Adolescent , Adult , Aged , Child , Humans , Middle Aged , Young Adult , Leprostatic Agents/administration & dosage , Leprosy, Lepromatous/drug therapy , Leprosy, Multibacillary/drug therapy , Leprosy, Tuberculoid/drug therapy , Clofazimine/administration & dosage , Clofazimine/adverse effects , Drug Therapy, Combination , Dapsone/administration & dosage , Dapsone/adverse effects , Leprostatic Agents/adverse effects , Prospective Studies , Rifampin/administration & dosage , Rifampin/adverse effectsABSTRACT
Lucio's phenomenon is defined as a variant of type 2 leprosy reaction. It is a rare event, occurring in the evolution of leprosy of Lucio and other forms of lepromatous leprosy. It has an exacerbated proliferation of Hansen bacilli in its pathophysiology, which invade blood vessel walls and injure endothelial cells, causing endothelial proliferation and decreasing the vascular lumen. This fact, associated with inflammatory reactions and changes in the coagulation system causes vascular thrombosis, ischemia, infarction and tissue necrosis, leading to the histopathological characteristic of the phenomenon. We report a case of lepromatous leprosy with irregular treatment that developed Lucio's phenomenon. Treatment with multidrug therapy, antibiotics, steroids and thalidomide achieved a favorable outcome.
Define-se o fenômeno de Lúcio como uma variante da reação hansênica do tipo 2. Evento raro, que ocorre na evolução da hanseníase de Lúcio e de outras formas de hanseníase virchowiana. Tem na sua fisiopatologia uma proliferação exacerbada dos bacilos de Hansen, que invadem a parede dos vasos sanguíneos e agridem as células endoteliais, causando proliferação endotelial e diminuição do lúmen vascular, fato este, que associado a reações inflamatórias e a alterações no sistema da coagulação, causa trombose vascular, isquemia, infarto e necrose tecidual, gerando as alterações histopatológicas características do fenômeno. Relatamos um caso de hanseníase virchowiana, com tratamento irregular, que desenvolveu o fenômeno de Lúcio. Recebeu tratamento com poliquimioterapia, antibióticos, corticosteróide e talidomida, evoluindo com desfecho clínico favorável.
Subject(s)
Humans , Male , Middle Aged , Leprosy, Lepromatous/etiology , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Brazil , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/drug therapy , Leprosy/complications , Leprosy/pathology , Skin Diseases/drug therapy , Skin Diseases/pathologyABSTRACT
Introducción. La afección testicular es frecuente en la lepra lepromatosa, daño que se incrementa cuando cursa con eritema nudoso leproso. Objetivo. Presentar un paciente con lepra lepromatosa y eritema nudoso leproso con grave compromiso testicular. Materiales y métodos. Se estudió un hombre de 28 años con lepra lepromatosa desde los 22, que durante la poliquimioterapia para la lepra presentó eritema nudoso leproso crónico que afectó ambos testículos y no respondió al manejo convencional. El dolor persistente obligó a practicar orquidectomía izquierda. Resultados. Este testículo presentaba atrofia tubular y fibrosis notorias, conglomerados de macrófagos espumosos, sin bacilos, hiperplasia focal de células de Leydig, endarteritis y arteritis linfocitaria y granulomatosa de vasos pequeños y medianos; estos cambios también estaban presentes en el epidídimo. Un estudio llevado a cabo dos años después de terminar su tratamiento y de la orquidectomía izquierda, demostró azoospermia, testosterona total normal, testosterona libre discretamente disminuida y hormonas lutropina (luteinizante) y folitropina (estimulante del folículo) elevadas. No había disminución de la libido ni de su actividad sexual. Se revisaron los conceptos generales sobre el eritema nudoso leproso y las alteraciones que la lepra produce en el testículo. Conclusión. La lepra lepromatosa puede conducir a hipogonadismo. Los programas de lepra deben contemplar esta complicación para corregir y evitar sus secuelas.
Introduction. Damage of testicles is frequent in lepromatous leprosy and worsened by the presence of erythema nodosum leprosum. Objective. A patient is presented who developed lepromatous leprosy and erythema nodosum leprosum with major testicular compromise. Material and methods. The 28-year-old male patient had lepromatous leprosy since age 22. During a polychemotherapy treatment for the lepromatous leprosy, he presented chronic erythema nodosum leprosum that affected both testicles; he did not respond to the conventional treatment. A left orchidectomy was performed to treat the persistent pain. Results. The extracted testis evidenced the following: tubular atrophy, extensive fibrosis, cumulus of foamy macrophages without rods, focal Leydig cell hyperplasia, linfocitary and granulomatous arteritis and endarteritis of small and medium size vessels. These changes were also observed in the epididymis. Two years after the polychemoterapy and the orchidectomy, the patient exhibited azoospermy, normal total testosterone, slightly diminished free testosterone and elevated levels of luteinizing hormone and follicle-stimulating hormone. No loss of libido or sexual activity was reported. General concepts of erythema nodosum leprosum were reviewed, as well as the pathologic changes produced by leprosy in the testis. Conclusion. Lepromatous leprosy may lead to hypogonadism. This condition is recommended for inclusion in leprosy diagnostic programs in order to detect and treat the consequences of the possible hypogonadism.